VOLUMETRIC INFUSION PUMP COLLEAGUE - Anvisa Record n ​​° 10068390320. All models (Mono and Triple Channel). 의 안전성 경고

Agência Nacional de Vigilância Sanitária (ANVISA)에 따르면, 해당 안전성 경고 는 Brazil 에서 Baxter Hospitalar Ltda 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 사례 ID
    1020
  • 날짜
    2010-05-21
  • 사례 국가
  • 사례 출처
    ANVISA
  • 사례 출처 URL
  • 비고 / 경고
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • 데이터 추가 비고
    On May 3, 2010, the US Food and Drug Administration (FDA) ordered the Baxter company to perform the recall and destruction of Colleague Infusion Pump equipment currently in use in the United States. According to the FDA and Baxter, the imposition of the recall was not motivated by any risk attributed to the product. The reason for the payment was the company's failure to comply with the deadline to finalize corrective actions in the software of the equipment marketed in the United States. The FDA has not yet set the deadline for the recall and together with Baxter discusses the best strategy in order to minimize problems for patients and not affect their safety. Baxter is expected to submit a written plan to the FDA by the end of May 2010. Anvisa requested the product registration holder (Baxter Hospitalar Ltda, Baxter's Brazilian subsidiary) to provide information on the situation of Colleague pumps in Brazil. According to the company, imported Colleague pumps (about 5,700 units) received software updates that were not implemented in the US. According to the company, these fixes solve problems in the equipment. In the medium term, Baxter Hospitalar Ltda will replace the software version of Colleague pumps with a new version (see P.1.7). Version P.1.7 will be finalized by 2011 and, after Anvisa's approval, will be implemented in all equipment commercialized in Brazil. Anvisa is monitoring the developments of the case with Baxter Hospitalar Ltda and has not yet determined the collection of Colleague infusion pumps commercialized in the country. The implementation of the measures by the company is being checked (software replacement) To date, there are no notifications of adverse events or technical complaints involving the product in Brazil. The case is being accompanied by the Technovigilance Unit (UTVIG / NUVIG / ANVISA) and new information will be released as soon as it is available. #### UPDATE: The field correction was completed by the company on 10/30/2014. According to the company, 7,731 units were corrected (out of a total of 8,943 units) - of 1,212 uncorrected equipment, 1,083 were not located by the company and 129 had no external movement (movement without "low" termination in the company's system).
  • 원인
    Equipment collection colleague infusion pumps determined by the food and drugs administration (fda), applicable only to the usa.
  • 조치
    To date, there is no evidence that the use of Colleague infusion pumps (Baxter company) in Brazil has been interrupted.

Manufacturer

  • Source
    ANVSANVISA